AstraZeneca PLC has already shut its Indian R&D site and has now decided to close an active pharmaceutical ingredient (API) unit in the country, following an application to the Drugs Controller General of India to retract its local manufacturing license for terbutaline sulfate (TBS), a beta 2 agonist used in asthma.
"TBS was manufactured predominantly for export and the company applied to withdraw the manufacturing licence due to low demand for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?